Prevalence of abdominal wall hernia in participants with abdominal aortic aneurysm versus peripheral arterial disease--a population-based study.

Small studies suggest an association between abdominal aortic aneurysms (AAAs) and hernias, possibly related to connective tissue weakness. We evaluated the association between AAA and abdominal wall hernia (AWH), using peripheral arterial disease (PAD) patients as controls, in Olmsted County, Minnesota. In a retrospective cohort study we queried the electronic medical records for the diagnosis of AAA. The resulting data were then queried for prevalence of AWH. The same set of queries was repeated for PAD. Occurrence of AWH in the 2 groups was compared using the chi-square test. Of the 187 151 patient records queried, 939 had AAA and 3465 had PAD. Abdominal wall hernia occurred in 157 (16.7%) patients with AAA and in 343 (9.9%) patients with PAD. Abdominal wall hernia was 1.7 times more prevalent in those with AAA versus PAD (P < .0001). A history of hernia may prompt screening for AAA in some patients.

Acute myocardial infarction in sickle cell disease: a systematic review.

Myocardial infarction in young adults is, in practice, a diagnosis of exclusion. Given the fact that most of the patients with sickle cell disease are young and have predisposition to painful crisis, they are often overlooked for myocardial infarction. These patients often have few or no traditional risk factors for coronary artery disease, and risk stratification tools such as the Thrombolysis in Myocardial Infarction (TIMI) and Global Registry of Acute Coronary Events (GRACE) models place these patients at low risk. Nonspecific changes on electrocardiogram are of little diagnostic value. Myocardial infarction is very often a missed diagnosis in patients with sickle cell disease. Diagnostic criteria, potential mechanisms, and management for acute myocardial infarction in patients with sickle cell disease are discussed.

Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.

Glycoprotein (Gp) IIb/IIIa inhibitors reduce morbidity and mortality in patients undergoing percutaneous coronary intervention (PCI) when added to aspirin and heparin. However, the benefits of Gp IIb/IIIa inhibition in patients pretreated with clopidogrel are less clear. We conducted a meta-analysis to determine the efficacy and safety of adding a Gp IIb/IIIa inhibitor to clopidogrel, aspirin, and heparin before PCI. Five trials were identified via electronic searches of the MEDLINE and Cochrane Central Register of Controlled Trials databases. The studies randomized a total of 5303 patients; 2654 received a Gp IIb/IIIa inhibitor. Two trials examined patients with acute coronary syndromes and 3 examined patients undergoing elective PCI. Loading doses of clopidogrel ranged from 375 to 600 mg. Follow-up ranged from 30 days to 1 year.Gp IIb/IIIa inhibition did not reduce the endpoints of death, myocardial infarction (MI), or target vessel revascularization (odds ratio [OR] = 0.84; 95% confidence interval [CI] = 0.58-1.22, P = 0.35 for death; OR = 0.86; 95% CI = 0.69-1.08, P = 0.19 for MI; and OR = 0.96; 95% CI = 0.81-1.15, P = 0.68 for target vessel revascularization). Analyses restricted to acute coronary syndromes trials yielded similar results (OR = 0.70; 95% CI = 0.33-1.48, P = 0.35 for death; OR = 0.78; 95% CI = 0.59-1.03, P = 0.08 for MI). Gp IIb/IIIa inhibition increased major and minor bleeding (OR = 1.35; 95% CI = 1.04-1.75, P = 0.02) driven by use of abciximab. There was no evidence of heterogeneity in the analyses.